ForumIAS LATEST
- 04 June | MGP Strategy Series | GS Paper 4 (Ethics) with AIR 7 A.R. Rajah Mohaideen Click Here to register for the session →
- 04 June | GS Advance Program begins from 4th June 2026 | First 2 classes open to all Click Here to register for the event →
- 05 June | MGP Strategy Series | GS Paper 3 Strategy Session with AIR 406 Mannat Luthra Click Here to register for the session
- 06 June | Open Orientation on Essay Guidance Program (EGP 2026) Click Here to register →
- 07 June | Open Orientation for Current Affairs for Mains 2026 Click Here to register →
- 07 June | Sociology Optional Strategy Session with AIR 10 Ujjwal Priyank Click Here to register →
News: The World Health Organization has granted prequalification to an additional Novel Oral Polio Vaccine Type 2 (nOPV2).
About Novel Oral Polio Vaccine Type 2 (nOPV2)
- It is an improved oral vaccine designed to prevent outbreaks caused by circulating vaccine-derived poliovirus type-2.
- The vaccine is used for active immunization in all age groups, especially during outbreaks of poliovirus type-2.
- Developed By: Global Polio Eradication Initiative
- Type: Live-attenuated oral vaccine targeting Polio type 2
- Aim of nOPV2
- To stop outbreaks of poliovirus type-2 in a safer and more effective way.
- To reduce the risk of vaccine-derived virus mutations.
- To strengthen global progress toward the eradication of polio.
- Key Features
- The vaccine is genetically more stable than the traditional monovalent oral polio vaccine type-2.
- The improved stability reduces the chance that the vaccine virus will mutate and cause new outbreaks.
- The vaccine provides strong intestinal immunity, which helps stop virus transmission quickly.
- It can be supplied in multi-dose vials (20- and 50-dose formats) suitable for high-volume vaccination programs.
- It has a shelf life of up to 24 months and can be kept at routine vaccine storage temperatures, facilitating use across a range of environments.
